ERBB2 and triple-negative breast carcinoma: Accordingly, high TILs have been demonstrated to be associated with a survival benefit only in HER2-positive or triple negative breast cancer patients treated with chemotherapy, alone or in combination with trastuzumab, but not in ER-positive, HER2-negative breast cancer (30).